5-alpha reductase type 2 Inhibitors
1 drugsAbout 5-alpha reductase type 2
5-alpha reductase type 2 is an enzyme that converts testosterone to dihydrotestosterone (DHT), a more potent androgen, playing a crucial role in male reproductive tissue development and function. Specifically, it is highly expressed in the prostate gland where it regulates androgen-mediated growth.
While there is currently no genetic evidence directly linking variations in the 5-alpha reductase type 2 gene to specific diseases, its role in androgen metabolism makes it a relevant drug target. Modulation of this enzyme's activity can influence conditions where androgen signaling is a contributing factor.
5-alpha reductase type 2 is targeted by one FDA-approved drug, AVODART (dutasteride), a small molecule used in other therapeutic areas. WAYLIS THERAP is the sole company with an approved drug for this target.
Top 5-alpha reductase type 2 Drugs
WAYLIS THERAP is the only company with an approved drug targeting 5-alpha reductase type 2.
The lack of competition suggests either high barriers to entry or limited market potential.
5-alpha reductase type 2 Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets 5-alpha reductase type 2, using small molecule modality.
Exploring alternative modalities like antibodies or PROTACs could provide a competitive advantage.
5-alpha reductase type 2 Clinical Trials 53 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on 5-alpha reductase type 2. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 19 | 16 | 2 | 1 | 89% |
| Phase 2 | 16 | 9 | 5 | 2 | 64% |
| Phase 3 | 8 | 6 | 0 | 2 | 100% |
| Phase 4 | 10 | 8 | 1 | 1 | 89% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
5-alpha reductase type 2 Drug Approval Timeline (2001 - 2001)
The first and only drug, AVODART, was approved in 2001.
The absence of recent approvals indicates a potentially saturated market or challenges in developing new therapies.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 31 (9 companies)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on 5-alpha reductase type 2. A trial counts if an approved drug acting on 5-alpha reductase type 2 is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.